Nanobiotix | MedPath

JNJ-1900 Shows Promise in Phase 1 Trial for Advanced Pancreatic Cancer

17 days ago

• JNJ-1900 (NBTXR3) demonstrated favorable safety and feasibility in a Phase 1 trial involving 22 patients with locally advanced or borderline resectable pancreatic cancer. • The trial showed encouraging efficacy with a median overall survival of 23 months from diagnosis, compared to 19.2 months with standard care in a historical review. • Exploratory biomarker analyses revealed CA19-9 normalization in 59% of patients, associated with improved survival, and increased circulating tumor mutational burden in 40% of patients.

Promising Pipeline for Soft Tissue Sarcoma Treatment Expands with 130+ Therapies in Development

2 months ago

• Global soft tissue sarcoma pipeline constitutes 125+ companies developing 130+ treatment therapies, with significant progress in clinical trials across various stages of development. • FDA grants Orphan Drug Designation to Actuate Therapeutics' elraglusib for soft tissue sarcoma treatment, highlighting its potential to address unmet needs in this rare cancer. • Novel approaches include tumor-targeting antibody-cytokine fusion proteins, intratumoral administration techniques, and GSK-3β inhibition, offering hope for improved outcomes in this challenging disease.

Nanobiotix's Radioenhancer JNJ-1900 Enters Phase 2 Trial for Unresectable NSCLC

4 months ago

• Nanobiotix has dosed the first patient in the CONVERGE study, a Phase 2 trial evaluating JNJ-1900 (NBTXR3) for Stage 3 unresectable non-small cell lung cancer. • The CONVERGE trial, sponsored by Janssen, assesses JNJ-1900 in combination with chemoradiation and durvalumab for patients with advanced NSCLC. • JNJ-1900, a novel radioenhancer, aims to improve tumor cell death and trigger an adaptive immune response when activated by radiotherapy. • Nanobiotix is also evaluating JNJ-1900 in a Phase 3 trial for head and neck squamous cell cancers, with FDA Fast Track designation for HNSCC.

BioNTech Advances Oncology Pipeline with BNT327/PM8002 and mRNA Immunotherapies

4 months ago

• BioNTech is progressing BNT327/PM8002, a bispecific antibody, into global clinical trials for first-line small cell lung cancer and non-small cell lung cancer. • The company plans to initiate additional trials combining BNT327/PM8002 with antibody-drug conjugates (ADCs) in 2025, expanding its combination strategy. • BioNTech's mRNA cancer immunotherapy, autogene cevumeran, is being evaluated in a Phase 2 trial for muscle-invasive urothelial carcinoma in combination with nivolumab. • Clinical data readouts are expected in 2025 and 2026 from multiple randomized trials of personalized and off-the-shelf mRNA cancer immunotherapy candidates.

Standard Chemoradiation Shows Superior Outcomes in HPV-Associated Oropharyngeal Cancer

8 months ago

• A phase II/III trial (NRG Oncology HN005) revealed a 98% two-year progression-free survival rate with standard chemoradiation for HPV-associated oropharyngeal cancer, a record high. • De-intensified treatments, involving lower radiation doses and immunotherapy (nivolumab) instead of chemotherapy, did not match the efficacy of standard chemoradiation. • Experts emphasize that de-intensification strategies should remain experimental, requiring further research to minimize side effects while maintaining high cure rates. • The findings set a new benchmark for progression-free survival expectations, challenging the validity of phase II trials using lower standards for this patient population.